In this podcast, we are pleased to have Mike Walsh, CEO of Patient Advocacy Strategies as our guest. Patient advocacy may seem like a “nice to have” or an afterthought.
In this podcast you’ll learn why the opposite is true – that it’s important to glean input from patient groups early on in the lifecycle and throughout the course of developing solutions for patients. Collecting insights from patient groups, you’ll learn, isn’t something to be done half-heartedly; without it, the risk of a strategic miss becomes highly elevated.
What inspired him to break out of corporate job roles in life sciences and become an entrepreneur
Why is it important for small, early stage companies to glean insights from patient groups early on in the lifecycle, even if they’re not in the clinic?
At what point in the lifecycle a company should look to include patient inputs in their product development.
How to build a patient community that is sustainable, proactive, and strategic about meeting the patient’s needs – and why it matters
The consequences when leadership conducts patient advocacy half-heartedly or doing it themselves when it’s not their primary function
Why great intentions and no follow through leads to missteps that compromise integrity
Why the role of AI in finding participants for clinical trials is overestimated
Enjoy the show!
Mike Walsh
Approaching 30 years of leadership in the life science industry, Mike is passionate about improving healthcare with proactive patient advocacy & engagement. After thriving in diverse, cross-functional roles at Amgen, Biogen, InterMune, Genentech and others, Mike crystalized his core professional and personal driver as patient centricity, and he founded Patient Advocacy Strategies in 2015.
As Founder & CEO of PAS, Mike and his team lead and counsel biotech companies and non-profit patient & disease organizations, forging trusted relationships with key opinion leaders, patient influencers, and advocacy groups. PAS provides strategic guidance, tactical execution and content development that manifests through patient-centric initiatives for companies from the pre-clinical stage to fully commercial biopharma.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Comments